Trial Profile
Portuguese Observational Re-Treatment Study of MabThera (PORTSMAB) - A Two-centre Observational Study in Sero-positive Rheumatoid Arthritis (RA) Patients Who Are Non-responders or Intolerant to a Single Tumor Necrosis Factor (TNF) Inhibitor.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms PORTSMAB
- Sponsors Roche
- 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 May 2013 Planned End Date changed from 1 Dec 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 04 Feb 2013 Planned End Date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.